NCT06112314Phase 3Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Study sponsor: Immunocore Ltd

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-10-16Estimated
Enrollment · participants680Estimated
Source updated2026-02-25Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview